Biology Beyond the Margins: Impact of 40-Gene Expression Profiling on Risk Stratification in Cutaneous Squamous Cell Carcinoma
Main Article Content
Keywords
Cutaneous Squamous Cell Carcinoma, gene expression profiling, 40-GEP, Metastasis, molecular diagnostics, case report, 40-gene expression profile (40-GEP)
Abstract
Background Cutaneous squamous cell carcinoma (cSCC) causes more annual mortality than metastatic melanoma. However, risk stratification protocols remain based solely on clinicopathologic features, excluding tumor biology. (Table 1)
Objective To illustrate how integration of 40-gene expression profile (GEP) testing influences prognostic assessment and post-treatment management in high-risk cSCC.
Methods We present a case report of a 70-year-old male whose incidental cSCC was reclassified as high-risk following 40-GEP testing despite histologic clearance, resulting in enhanced surveillance.
Results Tumor profiling yielded a Class 2A (higher risk) result, which altered post-operative follow-up strategies beyond conventional staging.
Conclusion Gene expression profiling provides valuable, individualized prognostic data, which may improve management of high-risk cSCC patients and should be considered for broader integration into clinical guidelines.
References
2. Wehner MR, Cidre Serrano W, Nosrati A, et al. All-cause mortality in patients with basal and squamous cell carcinoma: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(4):663-672.e3.
3. Karia PS, Han J, Schmults CD. Cutaneous Squamous cell carcinoma: estimated incidence, nodal metastasis, and mortality in the U.S. J Am Acad Dermatol. 2013;68(6):957-966.
4. Amin MB, Edge SB, Greene FL, et al.,eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. Springer; 2017.
5. National Comprehensive Cancer Network (NCCN). Squamous Cell Skin Cancer (Version 2.2025). NCCN Clinical Practice Guidelines in Oncology. Published 2025. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1443
6. Jambusaria-Pahllajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402-410. doi:10.1001/jamadermatol.2013.2036
7. Singh G, Tolkachjov SN, Farberg AS. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Clin Cosmet Investig Dermatol. 2023;16:925-935.
8. Sutton A, Wysong A. High-Risk Cutaneous Squamous Cell Carcinomas: The Present and Future. ASCO Post. February 10, 2021.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.